SYDNEY and BEDMINSTER, N.J., Jan. 16 2013 /PRNewswire/ — QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the steps necessary for approval of immediate release MoxDuo have been clarified with the United States Food and Drug…

SYDNEY and BEDMINSTER, N.J., Jan. 16 2013 /PRNewswire/ — QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the steps necessary for approval of immediate release MoxDuo have been clarified with the United States Food and Drug…

SYDNEY and BEDMINSTER, N.J., Jan. 16 2013 /PRNewswire/ — QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the steps necessary for approval of immediate release MoxDuo have been clarified with the United States Food and Drug…

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies that can be turned “on” or “off” with a goal to…

DUBLIN–(BUSINESS WIRE)–The "Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com’s offering. T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then

Minutes of the CAT meeting 22-24 May 2024

**Refined Title: Innovative Sneezing Mechanism in Squirrels: Potential Implications for Biotech** In the intricate world of biotechnology, unexpected biological phenomena can sometimes lead to groundbreaking innovations. One such curiosity is the voluntary sneezing mechanism observed in a species of squirrel, recently highlighted in Nature’s archives. Understanding this unique biological feature could unveil new pathways for

Telix unveils radiopharmaceutical spinoff Rhine Pharma following string of nuclear medicine acquisitions
fkansteiner
Tue, 10/22/2024 – 14:31

The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.